Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma. | Clin Cancer Res;27(12): 3503, 2021 Jun 15. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.

Armstrong, Andrew J; Nixon, Andrew B; Carmack, Andrea; Yang, Qian; Eisen, Tim; Stadler, Walter M; Jones, Robert J; Garcia, Jorge A; Vaishampayan, Ulka N; Picus, Joel; Hawkins, Robert E; Hainsworth, John D; Kollmannsberger, Christian K; Logan, Theodore F; Puzanov, Igor; Pickering, Lisa M; Ryan, Christopher W; Protheroe, Andrew; George, Daniel J; Halabi, Susan.

Clin Cancer Res ; 27(12): 3503, 2021 Jun 15.

Article in En | MEDLINE | ID: mdl-34117029

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article